Distributed Health Data Networks A Practical and Preferred Approach to Multi-Institutional Evaluations of Comparative Effectiveness, Safety, and Quality of Care

Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA 02215, USA.
Medical care (Impact Factor: 2.94). 06/2010; 48(6 Suppl):S45-51. DOI: 10.1097/MLR.0b013e3181d9919f
Source: PubMed

ABSTRACT Comparative effectiveness research, medical product safety evaluation, and quality measurement will require the ability to use electronic health data held by multiple organizations. There is no consensus about whether to create regional or national combined (eg, "all payer") databases for these purposes, or distributed data networks that leave most Protected Health Information and proprietary data in the possession of the original data holders.
Demonstrate functions of a distributed research network that supports research needs and also address data holders concerns about participation. Key design functions included strong local control of data uses and a centralized web-based querying interface.
We implemented a pilot distributed research network and evaluated the design considerations, utility for research, and the acceptability to data holders of methods for menu-driven querying. We developed and tested a central, web-based interface with supporting network software. Specific functions assessed include query formation and distribution, query execution and review, and aggregation of results.
This pilot successfully evaluated temporal trends in medication use and diagnoses at 5 separate sites, demonstrating some of the possibilities of using a distributed research network. The pilot demonstrated the potential utility of the design, which addressed the major concerns of both users and data holders. No serious obstacles were identified that would prevent development of a fully functional, scalable network.
Distributed networks are capable of addressing nearly all anticipated uses of routinely collected electronic healthcare data. Distributed networks would obviate the need for centralized databases, thus avoiding numerous obstacles.

Download full-text


Available from: Ross Lazarus, Oct 24, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: The Agency for Healthcare Research and Quality, in expanding its efforts to advance methods for comparative effectiveness research (CER), convened a second invitational symposium in June 2009 through its Developing Evidence to Inform Decisions About Effectiveness (DEcIDE) network. A distinguished Planning Committee set the agenda, reviewed more than 70 abstracts, and invited almost 30 speakers; the program emphasized issues of clinical heterogeneity and longitudinal outcomes, including patient-reported measures. RESULTS: Conference papers covered a varied set of points about 3 major areas of CER: study design and data collection issues; statistical and analytic techniques; and applications to policy and clinical decision-making. Both primary data collection and analyses of databases (including electronic health records and distributed networks) are crucial for the CER agenda. Methods advances enable investigators to pay greater attention to important population subgroups, including persons of low literacy, non-English speaking patients, or the frail elderly. Both established and newer statistical techniques--eg, propensity scoring and various types of modeling, including Bayesian approaches--offer analysts improved ways to address issues such as confounding and measurement bias. Finally, some articles provided guidance for and examples of extending CER into newer realms, such as evaluations of medical devices or surgical procedures, and providing better information for decision-makers, clinicians, and patients.
    Medical care 06/2010; 48(6 Suppl):S3-6. DOI:10.1097/MLR.0b013e3181e10434 · 2.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Active surveillance for potential drug safety issues requires access to observational healthcare data to identify and evaluate the association between drugs and subsequent outcomes. This study assessed the availability and content of observational data, as well as the interest of the data holder in participating in drug safety surveillance.Methods Between January and June 2009 we conducted a two-stage online survey of data holders. The surveys evaluated characteristics of the data sources and populations, as well as the experience of the organization in conducting drug safety evaluations and research. The first-stage ten-question survey was designed to capture basic information about the size of source population and types of data elements available and gauge interest in further participation in this research. The second-stage 70-question survey provided a comprehensive, quantitative and qualitative summary of population characteristics, data capture of drugs, health outcomes, procedures, visits and laboratory results, as well as a descriptive review of the organization's evaluation and research experience, infrastructure and process and interest in drug safety surveillance.Results Of the 70 US organizations that were contacted, 37 agreed to participate in the first stage of the survey. Of these, 26 reported access to data for over 1 million persons, and 9 reported more than 10 million persons. Respondents reflected a wide range of data stakeholders, including claims data aggregators, hospital benchmarking organizations, fiscal intermediaries that reimburse claims and integrated healthcare systems. Among the 21 organizations completing the second-stage survey, the aggregate data represented 540 million persons, 257 million of them currently active. Data sources showed significant variation in size (ranging from 34 000 to 160 million lives) and demographics of underlying populations, length of follow-up and completeness of data capture. Respondents had a median of 9 years coverage across the population, with a maximum of 51 years, and databases utilizing claims data tended to have a lower average length of capture than those using electronic health records. Data holders varied in interest and ability to conduct drug safety surveillance.Conclusions Multiple observational databases are needed to meet the requirements for an active drug safety surveillance system. Developing a network of disparate data sources requires careful consideration of the complementary nature of the underlying data and the necessary infrastructure to support coordination across the diverse stakeholder groups.
    Pharmaceutical Medicine 07/2010; 24(4):231-238. DOI:10.1007/BF03256821
  • New England Journal of Medicine 02/2011; 364(6):498-9. DOI:10.1056/NEJMp1014427 · 54.42 Impact Factor
Show more